- Home
- NNY vs ACTU Comparison
NNY vs ACTU Comparison
Compare NNY & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ACTU
- Stock Information
- Founded
- NNY 1987
- ACTU 2015
- Country
- NNY United States
- ACTU United States
- Employees
- NNY N/A
- ACTU N/A
- Industry
- NNY Investment Managers
- ACTU
- Sector
- NNY Finance
- ACTU
- Exchange
- NNY Nasdaq
- ACTU NYSE
- Market Cap
- NNY 155.1M
- ACTU 135.0M
- IPO Year
- NNY N/A
- ACTU 2024
- Fundamental
- Price
- NNY $8.05
- ACTU $7.47
- Analyst Decision
- NNY
- ACTU Strong Buy
- Analyst Count
- NNY 0
- ACTU 1
- Target Price
- NNY N/A
- ACTU $20.00
- AVG Volume (30 Days)
- NNY 50.9K
- ACTU 88.2K
- Earning Date
- NNY 01-01-0001
- ACTU 05-15-2025
- Dividend Yield
- NNY 4.04%
- ACTU N/A
- EPS Growth
- NNY N/A
- ACTU N/A
- EPS
- NNY N/A
- ACTU N/A
- Revenue
- NNY N/A
- ACTU N/A
- Revenue This Year
- NNY N/A
- ACTU N/A
- Revenue Next Year
- NNY N/A
- ACTU N/A
- P/E Ratio
- NNY N/A
- ACTU N/A
- Revenue Growth
- NNY N/A
- ACTU N/A
- 52 Week Low
- NNY $7.58
- ACTU $5.51
- 52 Week High
- NNY $8.87
- ACTU $11.99
- Technical
- Relative Strength Index (RSI)
- NNY 37.34
- ACTU N/A
- Support Level
- NNY $7.77
- ACTU N/A
- Resistance Level
- NNY $8.11
- ACTU N/A
- Average True Range (ATR)
- NNY 0.21
- ACTU 0.00
- MACD
- NNY -0.01
- ACTU 0.00
- Stochastic Oscillator
- NNY 27.45
- ACTU 0.00
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About ACTU ACTUATE THERAPEUTICS INC
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.